{'52WeekChange': -0.35172415,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Chemin des Mines, 9',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 10.1,
 'askSize': 900,
 'averageDailyVolume10Day': 3325,
 'averageVolume': 696,
 'averageVolume10days': 3325,
 'beta': 0.84593,
 'beta3Year': None,
 'bid': 9.4,
 'bidSize': 900,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Geneva',
 'companyOfficers': [],
 'country': 'Switzerland',
 'currency': 'USD',
 'dateShortInterest': None,
 'dayHigh': 11.2216,
 'dayLow': 8.31,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 41781176,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '41 22 884 1556',
 'fiftyDayAverage': 8.9002285,
 'fiftyTwoWeekHigh': 14.5,
 'fiftyTwoWeekLow': 6.19,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3123554,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 19,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': None,
 'heldPercentInstitutions': None,
 'industry': '',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/addextherapeutics.com',
 'longBusinessSummary': 'Addex Therapeutics Ltd, a development-stage '
                        'biopharmaceutical company, discovers, develops, and '
                        'commercializes small-molecule pharmaceutical products '
                        'for central nervous system (CNS) disorders in '
                        'Switzerland. The company focuses on the discovery of '
                        'oral small molecule allosteric modulators of '
                        'G-protein coupled receptors. Its lead programs '
                        "include Dipraglurant for the treatment of Parkinson's "
                        'disease levodopa-induced dyskinesia, and dystonia; '
                        'ADX71149 for epilepsy and undisclosed CNS disorders; '
                        'and GABAB PAM for addiction. It has license and '
                        'collaboration agreement with Janssen Pharmaceuticals '
                        'Inc. to develop mGluR2PAM compounds for the treatment '
                        'of human health. The company was formerly known as '
                        'Addex Pharmaceuticals Ltd and changed its name to '
                        'Addex Therapeutics Ltd in March 2012. Addex '
                        'Therapeutics Ltd was founded in 2002 and is '
                        'headquartered in Geneva, Switzerland.',
 'longName': 'Addex Therapeutics Ltd',
 'market': 'us_market',
 'marketCap': None,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_2573627',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1561852800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 8.31,
 'openInterest': None,
 'payoutRatio': None,
 'pegRatio': None,
 'phone': '41 22 884 1555',
 'previousClose': 7.64,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 11.2216,
 'regularMarketDayLow': 8.31,
 'regularMarketOpen': 8.31,
 'regularMarketPreviousClose': 7.64,
 'regularMarketPrice': 8.31,
 'regularMarketVolume': 24198,
 'revenueQuarterlyGrowth': None,
 'sector': '',
 'sharesOutstanding': None,
 'sharesPercentSharesOut': None,
 'sharesShort': None,
 'sharesShortPreviousMonthDate': None,
 'sharesShortPriorMonth': None,
 'shortName': 'Addex Therapeutics Ltd',
 'shortPercentOfFloat': None,
 'shortRatio': None,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ADXN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 8.915306,
 'volume': 24198,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.addextherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '1202'}